A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Items 401–500 of 602
Shinkins, B., Allen, A. J., Karichu, J. K., Garrison, L. P., & Monz, B. U. (2024) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00855-z · Cited by 8
Costo-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia
Rosselli, D., Castaño, N., Arciniegas, J. A., Peña, Á. A. G., Múñoz, Ó., & Gómez–Restrepo, C. (2015) · Acta Médica Colombiana · doi:10.36104/amc.2015.461 · Cited by 8
Prevention Programmes Cost-Effectiveness Review: Physical activity
Ce, L., Ubido, J., Holford, R., & Scott-Samuel, A. (2010) · Liverpool John Moores University · Cited by 8
The CHD challenge: Comparing four cost-effectiveness models
Turner, D., Raftery, J. P., Cooper, K., Fairbank, E., Palmer, S., Ward, S. E., & Ara, R. (2011) · Value in Health · doi:10.1016/j.jval.2010.10.009 · Cited by 8
“Comparison was aided by the fact that two of three comparator models were published as Health Technology Assessment (HTA) monographs [7,9] and these are considerably more detailed than most journal articles.”
Self-citationGoodwin, V. A., Hill, J. J., Fullam, J., Finning, K., Pentecost, C., & Richards, D. A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026289 · Cited by 8
Tabagisme, vapotage et risque cardiovasculaire : mise au point
Dalkou, S., & Clair, C. (2017) · JMIG · doi:10.53738/revmed.2017.13.566.1186 · Cited by 8
Ahola, T. L., Kantola, I. M., Puukka, P. J., Kattainen, A., Klaukka, T., Reunanen, A., & Jula, A. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328336a138 · Cited by 8
Peñaloza-Ramos, M. C., Jowett, S. M., Sutton, A. J., McManus, R. J., & Barton, P. M. (2017) · Value in Health · doi:10.1016/j.jval.2017.03.003 · Cited by 8
“Following NICE Statin guidelines (45) it was assumed that CVD is a combined state consisting of CHD (MI and UA) and stroke.”
Has cost inhibited the uptake of more potent statins in England?
Chapman, S., Fitzpatrick, R. W., & Aladul, M. I. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4231 · Cited by 8
D’Andrea, E., Nagyová, I., & Villari, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-13620-2_4 · Cited by 8
Wang, S.-L., Wang, C., Wang, P., Xu, H., Chen, K., & Shi, D. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/639267 · Cited by 8
“05 [30, 33, 59, 62]”
Lehane, E. A., McCarthy, G. M., Collender, V., Deasy, A., & O’Sullivan, K. (2013) · Journal of Nursing Measurement · doi:10.1891/1061-3749.21.1.64 · Cited by 8
“Efficacious pharmacological therapy exists to manage the condition (Ford et al., 2007; Ward et al., 2007), yet significant levels of nonadherence continue to be reported (Albert, 2008; Kulkarni, Alexander, Lyttle, Heiss, & Peterson, 2006).”
BackgroundNicoletti, R., Buommino, E., & Tufano, M. A. (2012) · Recent Patents on Biotechnology · doi:10.2174/187220812801784687 · Cited by 8
Lee, J., Han, A., Choi, D., Lim, K., & Bae, S. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013292 · Cited by 8
Cost-effectiveness of pharmacotherapy for smoking cessation
Shahab, L. (2011) · UCL Discovery (University College London) · Cited by 8
Statins for the primary prevention of cardiovascular disease
Taylor, F. C., Ward, K. J., Moore, T. H., Burke, M., Smith, G. D., & Ebrahim, S. B. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub3 · Cited by 8
Statin use and outcome after intracerebral hemorrhage: Case-control study and meta-analysis
Herrington, W. G., Rosand, J. M., Biffi, A., & Greenberg, S. M. (2011) · Neurology · doi:10.1212/wnl.0b013e318239be24 · Cited by 8
Electrocardiogram Risk Score and Prevalence of Subclinical Atherosclerosis: A Cross-Sectional Study
Kang, M., Chang, Y., Kang, J., Kim, Y., & Ryu, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030463 · Cited by 7
“Detecting the preclinical stage of CVD is crucial to prevent the progression of CVD since it enables early intervention nd treatment [17].”
BackgroundInfluentialCunico, C., Picheth, G., Correr, C. J., & Scartezini, M. (2014) · Pharmacy Practice · doi:10.4321/s1886-36552014000200002 · Cited by 7
Cost driver analysis of statin expenditure on Australia’s Pharmaceutical Benefits Scheme
Thai, L. P., Moss, J. R., Godman, B., & Vitry, A. I. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1136790 · Cited by 7
“mary prevention, the cost–effectiveness ratios are dependent on a number of risk factors but still support aggressive treatment recommendations [63].”
BackgroundCole, A., Stephens, K. A., West, I. I., Keppel, G. A., Thummel, K. E., & Baldwin, L. (2018) · Health Informatics Journal · doi:10.1177/1460458218813640 · Cited by 7
Yang, J., Xu, X., Han, S., Qi, J., Li, X., Pan, T., Zhang, R., & Han, Y. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05069-2 · Cited by 7
Rodine, R. J., Tibbles, A. C., Kim, P. S., & Alikhan, N. (2010) · Europe PMC (PubMed Central) · Cited by 7
Taylor, R. S., Murphy, K., Kirson, N. Y., Pfefferkorn, J., Kirtane, A. J., Azizi, M., & Neumann, P. (2025) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2025.103601 · Cited by 6
Khattar, R. S., Nair, S. B., Hamid, T., Chacko, S. M., Mamas, M. A., Turkie, W., & Arumugam, P. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711404505 · Cited by 6
Veličković, V. M., Rochau, U., Conrads‐Frank, A., Kee, F., Blankenberg, S., & Siebert, U. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1512857 · Cited by 6
“[31] Mainly assumptions Vaidya [61] Bad Nauheim Acute Coronary Syndrome II Registry, Germany (unpublished results) Selmer et al.”
BackgroundMethodHainsworth, R., Thompson, A., Guthrie, B., Payne, K., & Rogers, G. (2024) · Medical Decision Making · doi:10.1177/0272989x231214782 · Cited by 6
“A systematic review of clinical and cost-effectiveness evidence for statins 23 partly informed the choice of HSUVs in the CG181 model.”
BackgroundHorváth, Z., Torday, L., Hitre, E., Ganofszky, E., Juhos, É., Czeglédi, F., Urbán, L., Polgár, C., Láng, I., Eckhardt, S., et al. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9344-9 · Cited by 6
Synthetic Approaches Towards Antihypercholesterolemic Drug Simvastatin
Fattah, T. A., Saeed, A., & Shehzadi, S. A. (2019) · Current Organic Synthesis · doi:10.2174/1570179416666190725095951 · Cited by 6
Assessing the Impact of Developments in Genetic Testing on Insurers' Risk Exposure
Rodriguez-Rincon, D., Parkinson, S., Hocking, L., Evans, H., Hudson, E., & Morley, K. I. (2022) · Rand health quarterly · doi:10.7249/rhq-09-04-05 · Cited by 6
Primary and secondary prevention of atherosclerotic cardiovascular disease: A case-based approach
Hariri, E. H., Hammoud, M. M. A., Nissen, S. E., & HAMMER, D. F. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21103 · Cited by 6
Simvastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014857 · Cited by 6
Recall dermatitis after systemic treatment with paclitaxel
Kazandjieva, J., Gergovska, M., Darlenski, R., Márina, S., Broshtilova, V., Balabanova, M., & Stransky, L. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04499.x · Cited by 6
Webber-Foster, R., Kvizhinadze, G., Rivalland, G., & Blakely, T. A. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0154-x · Cited by 6
Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?
Ferdinand, K. C. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0149-9 · Cited by 6
Charland, S. L., & Stanek, E. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1368 · Cited by 6
“9 A search of the MEDLINE database was then performed (January 2001–June 2009) by modifying a previously developed comprehensive search strategy from a health technology assessment of statin therapy for cardiovascular event prevention, with the addition of the following Medical Subject Heading terms: all statin brand…”
MethodKrüse, V., Denys, H. G., den Broecke, R. V., Belle, S. V., & Cocquyt, V. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-202 · Cited by 6
Breeze, P. R., Thomas, C., Squires, H., Brennan, A., Greaves, C. J., Diggle, P., Brunner, E. J., Tabák, Á. G., Preston, L., & Chilcott, J. B. (2015) · Diabetic Medicine · doi:10.1111/dme.12981 · Cited by 6
RetractedXu, Q., Li, Y., Jiejing, Z., Jian, L., Li, Q., Lingya, C., Ying, L., Changchen, S., Li, Y.-L., & Wei, Y. (2021) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-021-00264-w · Cited by 6
Dickinson, R. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 6
Taha, E. I. (2014) · Drug Delivery · doi:10.3109/10717544.2014.947049 · Cited by 5
“SIM is only available in tablets dosage form, with dose ranging from 20 to 80 mg/d. SIM has been proved to decrease total mortality risk by reducing death caused by coronary heart disease and lowering the risk of myocardial infarction (Ward et al., 2007).”
BackgroundPravastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., Tasnim, S., & Wright, J. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013673 · Cited by 5
Fluvastatin for lowering lipids
Adams, S. P., Sekhon, S. S., Wright, J. M., & Tsang, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012282 · Cited by 5
Santana, I. A. D., de Oliveira, J. A., Lima, J. M. D. S., Testa, L., Piato, J. R. M., Hoff, P. M., & Mano, M. S. (2014) · Breast Cancer · doi:10.1007/s12282-014-0564-9 · Cited by 5
den Engelsen, C., Gorter, K. J., Salome, P. L., & Rutten, G. E. H. M. (2012) · Family Practice · doi:10.1093/fampra/cms052 · Cited by 5
Almufarrij, I., Munro, K. J., & Dillon, H. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038113 · Cited by 5
Ara, R., Rafia, R., Ward, S. E., Wierzbicki, A. S., Reynolds, T., Rees, A., & Pandor, A. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.42 · Cited by 5
Self-citationGao, L., Li, S., & Moodie, M. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.7995 · Cited by 5
Pitavastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012735 · Cited by 5
Expression of endoglin and podoplanin in early and advanced oral squamous cell carcinoma
Lee, S.-W., & Park, Y. (2012) · 대한구강악안면외과학회지 · doi:10.5125/jkaoms.2012.38.3.145 · Cited by 5
The Role of Drug Transporters in Statin-Induced Myopathy
Knauer, M. J. (2012) · Scholarship@Western (Western University) · Cited by 5
Benefit–risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment
Wanishayakorn, T., Sornlertlumvanich, K., & Ngorsuraches, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009387 · Cited by 5
Montouchet, C., Ruff, L., & Balu, S. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.801350 · Cited by 4
Lovastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014858 · Cited by 4
Shuja, D., Mian, M. U., Dhanjal, M. K., Mengar, J., Butt, A. A., Chaudhari, S. S., Wei, C. R., & Khan, A. A. (2024) · Cureus · doi:10.7759/cureus.68602 · Cited by 4
“The decision can also be influenced by factors such as cost, patient preference, and availability of the medication [21-22].”
BackgroundThe Economics of Cardiovascular Disease in the United States
Chen, J., & Rizzo, J. A. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2011.10.007 · Cited by 4
Guideline Confusion for the Clinician
Whayne, T. F. (2014) · Angiology · doi:10.1177/0003319714559122 · Cited by 4
“An explanation of this discrepancy is run-in phases where all participants take the statin to be studied and then anyone with a problem is eliminated before the randomization phase.(29) Concern has been raised regarding possible conflicts of interest involving some panelists who wrote the ACC/AHA 2013 guideline.”
BackgroundWright, D. N. M., Milne, R., Price, A., & Tose, N. (2013) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646231300010x · Cited by 4
“A systematic review and economic evaluation of statins for the prevention of coronary events (19) Technology assessment report 166,652 7,960 22.”
BackgroundBejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.001 · Cited by 4
“Economic assessment shows that statins are cost-effective compared with nonactive treatment in the secondary prevention of CVD and in primary prevention in high-risk patients, but their cost-effectiveness is less clear as risk decreases.(14) Thus, it is important to determine the economic impact of the drastic change…”
BackgroundReview: Does lowering cholesterol have an impact on the progression of aortic stenosis?
Greve, A. M., & Wachtell, K. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708093935 · Cited by 4
“…the processes related to cholesterol and the possible mechanisms by which statins can counteract the progression of AS. Abundant data support statin effect in lowering plasma LDL and improving outcome in ischemic heart disease and thromboembolic stroke [O’Regan et al. 2008; Ward et al. 2007].”
BackgroundMeasuring LDL-cholesterol: are we doing it wrong?
Stek, S., Tax, M., & Verheijen, F. W. (2012) · Cited by 4
Patel, S. R., O’Donnell, C., & Fbcla, F. (2012) · Cited by 4
Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran
Amirsadri, M., & Torkpour, E. (2023) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.367799 · Cited by 4
Lipid-Lowering Therapy in PURE Poland Cohort Study
Lubieniecki, P., Wołyniec, M., Połtyn–Zaradna, K., Zatońska, K., & Szuba, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010060 · Cited by 4
“There are a number of studies showing a significant effect of statins and other hypolipemic drugs in reducing cardiovascular events [6–8].”
BackgroundHuang, W.-T., Chen, H.-H., Yeh, C.-H., Lu, Y.-C., Hwang, W.-S., Huang, J., Chen, C.-P., Lin, P., Uen, W.-C., Lee, Y.-C., et al. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182a6799d · Cited by 4
Bejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2015) · Revista Española de Salud Pública · doi:10.4321/s1135-57272015000100003 · Cited by 4
“Economic assessment shows that statins are cost-effective compared with nonactive treatment in the secondary prevention of CVD and in primary prevention in high-risk patients, but their cost-effectiveness is less clear as risk decreases.(14) Thus, it is important to determine the economic impact of the drastic change…”
BackgroundBozinoff, N., Soobiah, C., Rodak, T., Bucago, C., Kingston, K., Klaiman, M., Poynter, B., Samuels, G., Schoenfeld, E. M., Shelton, D., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053207 · Cited by 4
Cardiovascular Risk Management in Clinical Practice: Time to Change
Volpe, M., Erhardt, L., & Williams, B. (2008) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200815010-00003 · Cited by 4
Bowater, R. J., Hartley, L., & Lilford, R. J. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.03.005 · Cited by 4
Neyeloff, J. L. (2012) · Lume (Universidade Federal do Rio Grande do Sul) · Cited by 4
Nuijten, M. J. C., Aultman, R., de Castro, J., Vergnenégre, A., CHOUAID, C., Walzer, S., & Siebert, U. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.626019 · Cited by 3
Gorevski, E., Bian, B., Kelton, C. M. L., Martin-Boone, J. E., & Guo, J. J. (2011) · Value in Health · doi:10.1016/j.jval.2011.07.005 · Cited by 3
Han, R., Liang, S., François, C., Aballéa, S., Clay, E., & Toumi, M. (2021) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2021.1887664 · Cited by 3
Choi, G., Kim, Y., Shin, G., & Bae, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052494 · Cited by 3
Price II, W. N. (2019) · eYLS (Yale Law School) · Cited by 3
Current controversies in the management of breast cancer
Tusquets, I., García‐Estévez, L., Adrover, E., Calvo, L., Álvarez, I., Mata, J. G., Fernández, Y., Margueli, M., Seguí, M. Á., Rodriguez, C. A., et al. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0504-x · Cited by 3
Generic Statins in Cardiovascular Medicine
Feher, A., Pusch, G., & Harang, G. (2011) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.s2-003 · Cited by 3
“Recently, the costeffectiveness of rosuvastatin have been shown in several economical studies above generic substitutions [26-28].”
BackgroundStatines in België: evolutie in het gebruik en invloed van het terugbetalingsbeleid
Roberfroid, D., Dubois, C., Vrijens, F., Camberlin, C., & Farfan-Portet, M.-I. (2010) · doi:10.57598/r141a · Cited by 3
Bejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Pediatría Atención Primaria · doi:10.4321/s1139-76322014000500015 · Cited by 3
Nowak, R., Kostrzewa‐Nowak, D., Jastrzębski, Z., Zarębska, A., Ficek, K., & Cięszczyk, P. (2016) · Human Movement · doi:10.1515/humo-2016-0030 · Cited by 3
“Some literature data showed that effective hyperlipidaemia management could substantially reduce cardiovascular morbidity and mortality [8].”
BackgroundDehmer, S. P. (2012) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 3
Screening for Metabolic Syndrome in Primary Care
den Engelsen, C. (2013) · Utrecht University Repository (Utrecht University) · Cited by 3
Type 2 diabetes: prevention and cure?
Pierce, M. B. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x661002 · Cited by 3
Shantsila, A., & Lip, G. Y. H. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02233.x · Cited by 3
Benefit-Risk Assessment of Statins (Lipid Lowering Agents): A Multi-Criteria Decision Analysis
Wanishayakorn, T., & Ngorsuraches, S. (2015) · Journal of Multi-Criteria Decision Analysis · doi:10.1002/mcda.1554 · Cited by 2
Control de los factores de riesgo y tratamiento de la enfermedad arterial oclusiva
Pont, C. L., & Clarà, A. B. I. (2009) · Anales de Cirugía Vascular · doi:10.1016/s1130-2542(09)70814-2 · Cited by 2
The euros and sense of stents: do we get value for money?
Annemans, L. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834da507 · Cited by 2
Edwards, L. A., Taylor, D. J., Campbell, P., Shah, R., Edgar, D. F., & Crabb, D. P. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030523 · Cited by 2
Almufarrij, I., Dillon, H., & Munro, K. J. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045899 · Cited by 2
Peters, J. L., Shepherd, J., Maund, E., Grigore, B., Woods, L., Lord, J., Scott, D. A., & Hyde, C. (2026) · Health Technology Assessment · doi:10.3310/gjjs3014 · Cited by 2
Li, K. K., Holbrook, A. M., Thabane, L., & Teo, K. K. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.02.019 · Cited by 2
Ortendahl, J. D., Harmon, A. L., Bentley, T. G. K., & Broder, M. S. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1336449 · Cited by 2
Cerivastatin for lowering lipids
Adams, S. P., Tiellet, N., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012501 · Cited by 2
Bejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.05.020 · Cited by 2
“Economic assessment shows that statins are cost-effective compared with nonactive treatment in the secondary prevention of CVD and in primary prevention in high-risk patients, but their cost-effectiveness is less clear as risk decreases.(14) Thus, it is important to determine the economic impact of the drastic change…”
BackgroundIs gemcitabine cost effective in cancer treatment?
Toschi, L., Finocchiaro, G., Ceresoli, G. L., Zucali, P. A., Cavina, R., Garassino, I. M. G., Vincenzo, F. D., Santoro, A., & Cappuzzo, F. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.3.239 · Cited by 2
Extended/supplementary prescribing: a public health perspective
O’Brien, S. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511861123.013 · Cited by 2
Masuo, K. (2015) · InTech eBooks · doi:10.5772/59862 · Cited by 2
Zechmeister‐Koss, I., Ara, R., Ward, S. E., & Stollenwerk, B. (2011) · Journal of Public Health · doi:10.1007/s10389-011-0440-4 · Cited by 2
“For details of the model see Ward et al. (2007) and Zechmeister et al. (2008).”
BackgroundMethodInfluentialSelf-citationStollenwerk, B., Gandjour, A., Lüngen, M., & Siebert, U. (2012) · The European Journal of Health Economics · doi:10.1007/s10198-012-0454-z · Cited by 2
“However, this issue is frequently addressed in decision models [17, 18].”
BackgroundUsing statins to treat ‘healthy’ patients: are we there yet?
Shah, B. M., Kemp, R., & Clearfield, M. B. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.5 · Cited by 2
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.